Schizophrenia Trial, Recruiting NCT05805397 Sponsor: Columbia University Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT05805397
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 65 years old
  • People who have been diagnosed with Schizophrenia or Schizoaffective Disorder according to standard diagnostic guidelines (DSM-5)
  • People who are medically and psychiatrically stable and being treated as an outpatient (not currently admitted to hospital)
  • People who are fluent in English

Who may not be able to join:

  • People who have a documented history of intellectual disability, or whose estimated premorbid IQ score is below 70
  • People who have had severe substance use issues in the past three months, as defined by standard diagnostic guidelines (DSM-5)
  • People who have a neurological condition that is causing disease affecting the brain
  • People aged 60 or older who score below 20 on a standard memory and thinking test (Mini Mental Status Exam), which may indicate mild to severe cognitive impairment associated with possible dementia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alice Saperstein, PhD, Columbia University

Phone: 646-774-8464

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 April 2024
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Motivation and Pleasure Scale (MAP); Goal Attainment Scaling (GAS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov